EUVIMEDEUVIMED entdecken
Crossref

A novel metabolic reprogramming strategy for the treatment of targeting to heart injury-mediated macrophages

ShuRui Chen, Xiang Luo, Yu Sun, Wen Jin, Rongrong He

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von ShuRui Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Intensive Care Unit, Cardiovascular Hospital, Guangdong Second Provincial General Hospital, China; Integrated Chinese and Western Medicine Po…. Hauptthemen laut MEDLINE: Myocardial Infarction, Heart Injuries. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

M1 macrophages polarization has been reported as the direct risk of acute myocardial infarction (AMI) occurrence and worsen AMI prognosis, especially for hyperinflammation-associated AMI. However, clinic treatments remain challenges, including off-target and side-effects. The development of enzyme mimetics could provide effective treatments for a wide variety of diseases. Herein, nanomaterials were used to create artificial hybrid nanozymes. In this study, we synthesized in situ zeolitic imidazolate framework nanozyme (ZIF-8zyme) with anti-oxidative and anti-inflammatory ability to repair microenvironment via reprogramming M1 macrophages polarization. In vitro study reported that a metabolic reprogramming strategy that the improvement of glucose import and glycolysis with ZIF-8zyme via inhibiting ROS levels led to a metabolic crisis within the macrophages. ZIF-8zyme shifted the polarization of M1 macrophages toward higher production of M2 phenotype, decreased proinflammatory cytokines secretion, and promoted significant survival of cardiomyocytes under hyperinflammation condition. Moreover, ZIF-8zyme elicits more potent macrophages-polarizing effects under hyperinflammation condition. Therefore, metabolic reprogramming strategy based on ZIF-8zyme is a promising AMI therapy, especially for hyperinflammation-associated AMI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionHeart InjuriesHumansMacrophagesAnti-Inflammatory AgentsOxidation-Reduction

Stichwörter der Autor:innen

Acute myocardial infarctionMacrophages polarizationROSZIF-8zyme

Substanzen

Anti-Inflammatory Agents

Autor:innen und Institutionen

  • Cardiac Intensive Care Unit, Cardiovascular Hospital, Guangdong Second Provincial General Hospital, China; Integrated Chinese and Western Medicine Postdoctoral Research Station, School of Medicine, Jinan University, Gua…
  • Cardiac Intensive Care Unit, Cardiovascular Hospital, Guangdong Second Provincial General Hospital, China.
  • Cardiac Intensive Care Unit, Cardiovascular Hospital, Guangdong Second Provincial General Hospital, China. Electronic address: jinwen020@126.com.
  • Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility, Jinan University, Guangzhou, China. Electronic address: Rongronghe@jnu.edu.cn.

Zitieren

APA

Chen, S., Luo, X., Sun, Y., Jin, W., & He, R. (2023). A novel metabolic reprogramming strategy for the treatment of targeting to heart injury-mediated macrophages. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110377

Vancouver

Chen S, Luo X, Sun Y, Jin W, He R. A novel metabolic reprogramming strategy for the treatment of targeting to heart injury-mediated macrophages. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110377

BibTeX
@article{Chen2023,
  author = {Chen, ShuRui and Luo, Xiang and Sun, Yu and Jin, Wen and He, Rongrong},
  title = {A novel metabolic reprogramming strategy for the treatment of targeting to heart injury-mediated macrophages},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110377}
}
Kostenlos starten →